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Background: A few recent studies have found indications of the effectiveness of inpatient psychotherapy for
depression, usually of an extended duration. However, there is a lack of controlled studies in this area and to date
no study of adequate quality on brief psychodynamic psychotherapy for depression during short inpatient stay
exists. The present article describes the protocol of a study that will examine the relative efficacy, the
cost-effectiveness and the cost-utility of adding an Inpatient Brief Psychodynamic Psychotherapy to
pharmacotherapy and treatment-as-usual for inpatients with unipolar depression.
Methods/Design: The study is a one-month randomized controlled trial with a two parallel group design and a
12-month naturalistic follow-up. A sample of 130 consecutive adult inpatients with unipolar depression and
Montgomery-Asberg Depression Rating Scale score over 18 will be recruited. The study is carried out in the
university hospital section for mood disorders in Lausanne, Switzerland. Patients are assessed upon admission, and
at 1-, 3- and 12- month follow-ups. Inpatient therapy is a manualized brief intervention, combining the virtues of
inpatient setting and of time-limited dynamic therapies (focal orientation, fixed duration, resource-oriented
interventions). Treatment-as-usual represents the best level of practice for a minimal treatment condition usually
proposed to inpatients. Final analyses will follow an intention–to-treat strategy. Depressive symptomatology is the
primary outcome and secondary outcome includes measures of psychiatric symptomatology, psychosocial role
functioning, and psychodynamic-emotional functioning. The mediating role of the therapeutic alliance is also
examined. Allocation to treatment groups uses a stratified block randomization method with permuted block. To
guarantee allocation concealment, randomization is done by an independent researcher.
Discussion: Despite the large number of studies on treatment of depression, there is a clear lack of controlled
research in inpatient psychotherapy during the acute phase of a major depressive episode. Research on brief
therapy is important to take into account current short lengths of stay in psychiatry. The current study has the
potential to scientifically inform appropriate inpatient treatment. This study is the first to address the issue of the
economic evaluation of inpatient psychotherapy.
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Depression is the largest contributor to the burden of
disease in high-income countries, with further increase
expected [1]. Depression may not respond to outpatient
treatment and may be so severe that hospital stay may
be needed [2,3]. Patients with severe symptoms benefit
more from acute inpatient treatment than from day-
hospital care [4]. Symptom improvement during first
inpatient treatment is a significant predictor of the
cumulative length of inpatient stay and the number
of inpatient episodes over five years [5]. Those results
are consistent with more recent literature that recom-
mends an intensive inpatient acute treatment of depres-
sion [3,6].
Due to the shift of locus of mental health care in most
Western countries towards outpatient care, research on
role and content of acute intensive inpatient psychiatric
care have received limited attention [7]. The vast
majority of depressed inpatients receive pharmacother-
apy, but receive psychotherapy less frequently [8-10].
Several meta-analyses support the advantage of combining
pharmacotherapy and psychotherapy to treat outpatients
with severe or complex depressive disorders [11-15]. The
only review of combined therapy for depressed inpatients
concluded that combined treatment appeared advanta-
geous in therapy-resistant, chronic and severe forms of
depressive disorders [16]. Its generalizability is limited by
relatively small sample sizes and heterogeneity in diag-
nosis of depression, though. The best well-controlled
study available in this field of research compared inter-
personal psychotherapy and pharmacotherapy vs. pharma-
cotherapy and clinical management for 124 inpatients
with major depressive disorder. This randomized con-
trolled trial showed that inpatient depression-specific
psychotherapy augmented pharmacotherapy [6].
Meta-analysis and mega-analysis findings support the
efficacy of brief psychodynamic therapy for outpatient
with depression [17-19]. While yet unsufficient, research
on efficacy and effectiveness of psychodynamic psycho-
therapy as a inpatient treatment of depression gives some
indications to foster examination of its validity. In a
review of 9 German studies, inpatient psychotherapy,
mostly psychodynamic, demonstrated good efficacy (aver-
age effect size, d = 0.84). Depression and obsessive-
compulsive disorders showed the best results, but usually
for psychotherapies of longer duration [20]. One cohort
study on a sample of 83 consecutive inpatients examined
the outcomes of short-term psychodynamic inpatient
psychotherapy. Over the course of the 4 weeks of
treatment, distress returned to normal range for 64% of
patients and remained stable one year later [21]. This
study had two major limitations. It was a complete ana-
lysis and it did not compare the treatment to a valid
comparator. Based on a randomized control trial with atwo parallel group design, one study explored the effi-
cacy of an interpersonal brief (5 weeks) and intensive
(15 individual and 8 group sessions) psychotherapy
program combined with pharmacotherapy compared to
medication and clinical management. Response rate
(70% vs 51%) and remission rate (49% vs. 34%) were
higher for psychotherapeutic group at discharge; after
the three-month follow-up the relapse rate (3% vs.
25%) also favored the psychotherapeutic group; finally
between treatment effect sizes evolved from moderate
(at discharge) to large during the follow-up period (3 and
12 months) [6]. Results for a subsample of 45 patients
with chronic depression revealed also a significantly
greater reduction of depressive symptoms, as well as
better global functioning [6,22].
Little systematic research has been conducted into the
ideal dosage of brief psychotherapy. Evidence come from
the outpatient setting. Between 12 and 18 sessions of
therapy are required for 50% of patients to improve,
according to a clinical significance perspective [23].
The Second Sheffield Psychotherapy Project found that
16 sessions were significantly more effective than 8 ses-
sions for patients with severe depression [24]. The nature
of the change aimed at should be taken into account,
however [23]. Recovery from maladaptive interpersonal
patterns, for example, typically requires higher doses of
psychotherapy than does recovery from symptoms of
depression or broader distress [25]. Changes at four
weeks of inpatient psychotherapy are equivalent to a
one-year follow-up for psychological distress but not
for interpersonal problems [6,26].
Inpatient psychiatric treatment has been under great
economic pressure to cut costs with the result of de-
crease in length of stay [27,28]. The brevity of inpatient
stay has lead to discard psychotherapy and hindered
examination of its potential cost-effectiveness. Research
in outpatient care has found that although the cost of
combination therapy in the initial treatment is substan-
tially higher, these costs are in part offset by lower sub-
sequent treatment costs [29-31]. Improvement during
the acute phase of treatment is important because it is
associated with lower subsequent costs across the full
range of mental health and general medical services [32].
Currently there is no study done on the economicity of
inpatient psychotherapy for depression.
In summary, current state of research support the
need for well-controlled trials to examine the effective-
ness and cost-effectiveness of inpatient acute treatment
of depression, including adjunctive brief dynamic ther-
apy to augment pharmacological treatment.
Objectives
The first purpose of the study is to estimate the relative
efficacy of combined inpatient brief psychodynamic
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to medication and clinical management on short- and
long-term outcomes of inpatients with severe, recurrent
or chronic depression (including so-called treatment-
resistant) according to the DSM-IVTR. The second
objective is to study the cost-effectiveness and the cost-
utility of the IBPP. The third objective is to document
the specific and the combined influence of the thera-
peutic alliance with the individual psychotherapist and
with the clinical team as mediators of patient’s change.Methods/Design
Study design
This trial is registered as: “Efficacy of an adjunctive brief
psychodynamic psychotherapy compared to treatment-
as-usual for psychiatric inpatients with unipolar major
depressive episode” at the Australian New Zealand
Clinical Trial Registy (ACTRN12612000909820). It has
been peer-reviewed in the successful funding selection
process by the Swiss National Science Foundation (Grant
32003B_135098/1). This protocol proposes a one month
randomized controlled trial (RCT) with a 12-month natur-
alistic follow-up. Figure 1 illustrates the two parallel group
design where patients included in the study are rando-
mized either to (1) the intervention group (adjunctive
short-term dynamic psychotherapy, IBPP), or to (2) the
control treatment group, which represents the best level
of practice for a minimal treatment condition usually
applied to hospitalized patients (treatment-as-usual, TAU).Inclusio
(during the first week of 
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Figure 1 Flow chart of the research plan.After the one month period, patients will be referred to
continuation treatment as usual.
Ethics approval
Ethics approval was granted by the Ethics Committee
of the University of Lausanne (12/04/2010).
Inclusion and exclusion criteria
All patients admitted in the university psychiatric
hospital section specialized for the treatment of mood,
anxiety and personality disorders are eligible to partici-
pate in the study if they meet the following inclusion
criteria: (1) Age 18–65 years old; (2) unipolar major
depressive episode; (3) Montgomery-Asberg Depression
Rating Scale > 18; (4) sufficient mastery of the French
language.
Exclusion criteria are: (1) Any organic medical disorder,
or persistent substance use/dependence which might
affect brain function (memory, level of consciousness,
cognitive abilities) thereby impairing the individual from
participating and benefiting from psychotherapy; (2) A
psychotic disorder which makes a pronounced break in
reality testing chronically or intermittently likely, such as
schizophrenia, delusional disorder, or bipolar manic-
depression (Type I); (3) Any of the following which are
considered unlikely to benefit from either treatment:
axis II paranoid, schizoid or schizotypal, and borderline
personality disorder, which are considered either contra-
indicated for some treatments, or unlikely to respond
[33]; antisocial personality characterized by frequentn
hospitalization)
tion    
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aggressiveness or violence; recent suicide attempts
necessitating residential or day treatment and acute risk
for suicide; other principal axis I disorder; severe cogni-
tive impairment; previous absence of response to the
study treatments.
Power calculation
Based on previous studies, at least moderate effect sizes
of psychodynamic psychotherapy on patient outcome
(e.g. f = .25 for severity of depressive symptomatology)
could be expected. Power analysis (with two-tailed alpha
set at .05 and a power of .80) for repeated measure
ANOVA indicates that 108 patients (54 in each group)
are sufficient to detect the expected effects [34]. With
22% of non-completers, an intent-to-treat sample of
138 patients (69 in each group) is required in order
to have a completer sample of 108 patients. All ana-
lysis will be done on the two samples.
Intervention and comparator
Psychosocial Treatment-As-Usual (TAU)
A manual (Preisig M, Lustenberger Y, Fassassi Gallo S,
Ambresin G, Viani I, Saraga M, Quément B: Manuel du
traitement psychiatrique intégré (Treatment-as-usual)
du patient déprimé hospitalisé, Unpublished manuscript,
Institute for Psychotherapy, Centre Hospitalier Universi-
taire Vaudois and University of Lausanne; 2007) which
follows the Practice guideline for the treatment of
patients with Major Depression of the American Psychi-
atric Association [2], contains all the treatments and pro-
cedures offered to patients. Treatment includes: (1) A
first interview of 45 minutes to define a treatment plan
made up of patient’s, nurses’, medical, and social objec-
tives. Therapeutic staff meets once a week to adapt it;
(2) Supportive interventions of 20 to 25 minutes (clinical
management), addressing psychopharmacological issues
when necessary, delivered twice a week by a psychiatric
resident; (3) Weekly two 30-minute encounters with nurses
aiming at developing the patient’s psycho-educational skills,
empowerment, and individualized treatment; (4) 6 psychoe-
ducation group sessions; (5) Social workers, ergo-, physio-,
and art-therapist interventions integrated into the treat-
ment as required by the patient’s needs; (6) Pharmacother-
apy following the rules of the World Federation of
Societies of Biological Psychiatry [35].
Inpatient Brief Psychodynamic Psychotherapy (IBPP)
Our manualized intervention model proposes a brief
psychodynamic intervention program in 12 sessions
over 4 weeks (Ambresin G, de Coulon N, Despland
JN: Traitement psychodynamique bref de la dépression
pour patient hospitalisé, Unpublished manuscript, Insti-
tute for Psychotherapy, Centre Hospitalier UniversitaireVaudois and University of Lausanne; 2008). Ses-
sions are 45 minutes long. It is based on the
Bush, Rudden & Shapiro (2004) manual of psycho-
dynamic treatment of depression to help the therapy
focalize on relevant depression foci [36]. For transfe-
rence, personality organization and conflictual themes
the intervention is based on Despland, Michel, & de
Roten (2010) manual on brief psychodynamic psycho-
therapy. Both manuals were adapted to the brief in-
patient setting [37]. Put briefly, the 12-session
psychotherapy approaches the crisis in the patient’s
intrapsychic and interpersonal equilibrium that led to
a hospital admission, within the context of depression
[38]. It focuses on both the patient’s conscious and
unconscious motives for admission. The initial hy-
pothesis is based on the dynamic relationship estab-
lished between the therapist and the patient during
the first three sessions (pre-transference), on the
patient’s present crisis, and on the dynamics that form
the core of his/her depressive episode. Following ses-
sions focalize further on helping the patient to gain a
better understanding of the psychological factors that
led to the emergence of depressive symptoms and to ad-
dress his/her vulnerability to those dynamics. Final
sessions address the patient’s feelings and fantasies
about termination as well as the decision regarding a
therapy of longer duration or long-term psychiatric
treatment if necessary.Outcome measures
As recommended in meta-analytic reviews, various
broad areas of patient’s functioning are assessed in-
cluding (1) psychopathology, (2) personality, social role
and quality of life, and (3) dynamic functioning which
may underlie impaired functioning and contribute to
vulnerability to psychiatric disorders [33]. Validated
French version is available for each of the following
questionnaires. Questionnaires are filled in with the
help of a research assistant. Due to their depressive
symptomatology, patients may face some difficulties
with self-report questionnaires. Therefore we have
restricted the total number of items included in the as-
sessment battery.Psychopathology
Depression Depressive symptoms are the primary out-
come. This is assessed by two instruments: (1) The
Montgomery-Asberg Depression Scale (MADRS; [39]),
a clinician rating measure in 10 items, which serves as
our primary outcome measure, and (2) the self-rated
version of the Inventory of Depressive Symptom (QIDS-
SR16; [40]), a 16-item self-report measure of depressive
symptoms. To allow for Kaplan-Meyer estimates of speed
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Depressive Experience Questionnaire (DEQ; Blatt SJ,
D’Afflitti J, Quinlan DM: Depressive Experiences Ques-
tionnaire, Unpublished research manual, Yale University;
1979) assesses a wide range of life experiences often
reported by depressed individuals but not considered
symptoms of depression. Its well-established factor struc-
ture measures two primary dimensions: interpersonal
relatedness and self definition.
Distress The Brief Symptom Inventory (BSI; [41])
derived from the Symptom Check-List (SCL-90-R) is a
widely used self-report measure of distress and psychi-
atric symptoms; the Global Assessment of Functioning
(GAF) is a numeric scale (0 through 100) used by an in-
dependent coder to rate the social, occupational and
psychological level of functioning.
Diagnosis The Diagnostic Interview for Genetic Studies
(DIGS; [42]) is used to collect diagnostic information.
This instrument enables the collection of extensive in-
formation on the course of psychiatric conditions in-
cluding mood and anxiety disorders. An updated version
of the DIGS includes DSM-IV criteria [43]. The reliabil-
ity of the French version was established in Lausanne for
major mood and psychotic disorders [44].
Early trauma Early childhood trauma is recognized
as the best predictor of response to psychotherapy
for severely depressed patients [45]. The childhood
Trauma Questionnaire Short-Form (CTQ-SF; [46]) pro-
vides a quick, multidimensional, retrospective measure
of childhood trauma with sound reliability and validity
characteristics.
Emotions Measured prior to therapy, alexithymia was
shown to be the best predictor of residual symptoms in
depressed patients who respond to short-term psycho-
therapy [47]. Alexithymia and other problematic patterns
of emotion processing is assessed by the Dimensions of
Emotional Openness (DOE; [48]).
Psychosocial role functioning
Interpersonal problems The Inventory of Interpersonal
Problems (IIP; [49]) is a self-report measure of problems
in interpersonal relationships, which is widely used in
psychotherapy research. We use the short version in 12
items and the main outcome is the total item-mean [50].
Social adjustment The Social Adjustment Scale Self-
Report (SAS-SR; [51]) assesses six areas of functioning
including work, social and leisure, extended family,intimate relations (e.g., spouse), parents, and family unit,
each on a six-point scale.
Dynamic personality functioning
Psychodynamic diagnosis and change The Operatio-
nalized Psychodynamic Diagnosis is a form of multiaxial
diagnostic system based on five axes: I = experience of
illness and prerequisites for treatment, II = interpersonal
relations, III = conflict, IV = structure and V = mental
and psychosomatic disorders [52]. To measure change in
this domain, we use the Heidelberg Structural Change
Scale (HSCS). Studies on content, criterion, and con-
struct validity indicate good validity for the individual
axes [53].
Defensive functioning The Defense Mechanism Rating
Scales (DMRS; [54]) is an observer-rated method for
quantitative ratings of 28 defense mechanisms. The
Overall Defensive Functioning (ODF) score then sum-
marizes the adaptive level of defensive functioning,
which is capable of detecting change over time, and pre-
dicts improvement in major depressive episodes [55].
Therapeutic alliance Inpatient setting requires differen-
tiating between two different forms of alliance. Alliance
with the individual therapist is assessed by the short
form of the Working Alliance Inventory Short-Form
(WAI-SF) in a revised version [56]. Alliance with the
treatment team is assessed by the Inpatient Treatment
Alliance Scale (I-TAS; [57]). For both instruments, we
use the patient self-rated version.
Cost-effectiveness data
Collection and management of the economic data are
fully integrated into the clinical data. Data will be
assessed at baseline (by ad hoc retrospective question-
naire), discharge (1 month), and at follow-up after
3 months and 12 months. Measures include:
Costs Information will be collected on inpatient and
outpatient direct costs (hospitalizations, emergency de-
partment visits, outpatient psychiatrist, psychotherapist,
physician, and other health care providers, and psycho-
tropic and nonpsychotropic prescriptions) and indirect
costs (productivity loss).
Quality of life (cost-utility analysis)
European Quality of Life-5 dimensions (EQ-5D) is a
short standardized patient-rated instrument measuring
health-related quality of life. The EQ-5D provides two
important aspects: a descriptive profile based on five
dimensions including mobility, self-care, usual activities,
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the profile by a visual analogue scale (EQ VAS).
Follow-up data (after 3 and 12 months)
Following termination of the active phase of treatment
(after the 4 weeks of psychotherapy or at discharge from
hospital), the vast majority of the patients are referred to
an outpatient unit for additional treatment or referred to
appropriate clinical services. In addition to the question-
naires, data is gathered concerning symptomatology, the
type and dose/frequency of pharmacological and psycho-
social ambulatory treatments, re-hospitalizations using the
Longitudinal Interval Follow-up Examination (LIFE; [58]).
Treatment integrity
Recording and transcription
All individual therapy sessions are audiotaped. Selected
sessions (1 early session – between Ss 2 to 4 and 1 late
session – between Ss 8 to 11) will be transcribed using a
standardized transcription method [59]. Adherence and
competence to IBPP will be assessed on selected sessions
with the following instruments: (1) The Psychotherapy
Process Q-Set (PQS ; Jones EE: Manual for the Psy-
chotherapy Process Q-set. Unpublished manuscript,
Berkeley, CA: University of California; 1975; [60]), a
rating scale assessing characteristic elements of a thera-
peutic session. which can be compared with the ideal
prototype of specific therapeutic methods (i.e., psycho-
analytic, cognitive-behavioral, family-systemic, brief psy-
choanalytic) An expert PQS prototype specific to the
IBPP will be developed and compared to the interper-
sonal and CBT prototypes [61]; (2) The Psychodynamic
Intervention Rating Scale (PIRS; Cooper S, Bond M:
Manual for the Psychodynamic Intervention Rating
Scale, Unpublished manuscript. Montreal: Institute of
Community and Family Psychiatry, Sir Mortimer B.
Davis - Jewish General Hospital; 2006), an instrument
elaborated specifically to investigate psychoanalytic psy-
chotherapies. It allows to distinguish interpretative inter-
ventions from other types of intervention, and to assess
the depth of understanding of interpretations on a five-
point scale.
Therapists’ selection and training
All psychotherapists (N between 10 and 15) are resident
psychiatrists in an advanced or completed stage of a
4-year psychotherapy training program in psychodynamic
psychotherapy and having attended training in brief psy-
chodynamic psychotherapy and IBPP. The IBPP training
course lasts two years (two hours weekly). The first year
includes theoretical presentation, role playing and case
presentation. The second year is devoted to group super-
vision. Training is delivered by three expert trainers of
the Lausanne University Medical School, who are agreedsupervisors for the psychodynamic psychotherapy and
authors of the IBPP manual.
Supervision
For the IBPP group, each therapist benefits from one
individual supervision each week, delivered by the same
three expert therapists that give the training. For the
TAU group, each psychiatrist will benefit from one hour
of individual supervision each week carried out by an
experienced psychiatrist of the unit.
Procedure
Data collection site
The hospital section specialized for the treatment of
mood, anxiety and personality disorders is a 40-bed unit,
which is part of the Department of Psychiatry of the
University of Lausanne. Patients are treated in a time-
limited program (mean duration stay = 26.2 days;
median = 20 days). This period is considered sufficient to
work through the crisis situation and its determinants
and to provide for adequate follow-up treatment refer-
ral when necessary. The length of the patient stay is
determined by the clinical staff, independently of the
research, i.e. the time of discharge does not depend on
the completion of psychotherapy, or after one month
for the comparison group. Only the post-treatment
measurement will be after one month, which is anyway
close to the mean patient stay (26.2 days).
Patients recruitment
All patients hospitalized in the clinical unit with a diag-
nosis of major unipolar depression are referred to the
project, interviewed for eligibility by a research assistant
(RA) and then given the intake assessment battery.
Patients giving informed consent (to be randomly assigned
to one of the treatment settings; to participate in the diag-
nostic and psychometric procedure; to agree, if necessary,
that psychotherapy sessions are audio recorded; and to
take part in the follow-up measurements) are then ran-
domized in one of the two treatment groups. Assessment
with the same instruments are also done after one month
of treatment (in a in- or partially out-patient setting),
then after 3 months and 12 months follow-up. Cases will
be considered as dropout if they had less than 5 sessions.
Study is currently continuing follow-up. It is closed to
recruitment of participants (as of June 2012).
Randomization
Allocation to treatment groups is done using a strati-
fied block randomization method with permuted block
(available at www.randomization.com). Three stratifica-
tion variables are used to ensure treatment balance [62]:
age (two levels: x<=40<y), gender (two levels: M/F), and
chronicity - that full criteria for a Major Depressive
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2 years (two levels: Y/N).
Blinding
To guarantee allocation concealment, randomization
was done by a totally independent researcher, and each
allocation was given to the recruiting RA in a sealed
envelope prior to seeing a new patient. The envelope
was opened if and only if the patient is included in
the protocol. Observers are blinded to treatment arm.
Rater training
DIGS are done by experienced raters working at the
Epidemiology and Psychopathology Research Unit, direc-
ted by one co-applicant (Prof. M. Preisig). Extensive
training is provided for the MADRS (one hour weekly
during three months) for the RAs. At the end of the
training, an inter-rater reliability of at least ICC(2,1) > .75
should be reached. Inter-rater reliability will be calcu-
lated for 20% of the cases. All raters are blind of the
clinical data.
Data analysis
Final analyses will follow an intention-to-treat strategy
comparing patients in the groups to which they were
originally randomized. Clinical Significance method will
be used to estimate rates of response (reliable improve-
ment), remission (clinical significance), recovery (main-
tained clinical significance) and relapse (deterioration)
[63]. For short-term outcome, repeated-measure ana-
lyses of variance (ANOVA) and analyses of covariance
(ANCOVA - controlling for pretreatment scores and
patient’s age) will be used on all outcome measures. For
long-term outcome, linear mixed-effects models will be
preferred, as well as for therapist and alliance effects on
outcome [64]. Last Observation Carried Forward (LOCF)
will be used for missing data when appropriate. Latent
class analysis (using Latent Gold 4.5) will be done to
explore the effect of moderating variables.
Cost-effectiveness analysis will be done in collaboration
with the Institute of Health Economics and Management
(IHEM) of the University of Lausanne. An economist at
the IHEM will be in charge of the data analysis. The eco-
nomic evaluation will be conducted from the perspective
of the health system. Primary outcome will be remission
in depressive symptomatology at 12 months. The com-
prehensively measured service costs between the two
treatments will be compared with the difference in
change in the primary outcome measure and with the
difference between the treatments in QALYs gained.
Discussion
Despite the large number of studies on treatment of
depression, there is a clear lack of controlled researchin inpatient psychotherapy during the acute phase of a
major depressive episode. Research on brief therapy is
important to take into account current short lengths
of stay in psychiatry. The current study has the poten-
tial to scientifically inform appropriate inpatient treat-
ment. Psychodynamic psychotherapy has shown some
promising signs of efficacy but more controlled studies
are strongly needed in order to be empirically validated
[65]. This is a very important issue, at least for European
countries like Switzerland, France or Germany where
psychoanalytic psychotherapy remains the most prac-
ticed form of therapy. It may also provide indications of
appropriate inpatient treatment to countries where in-
patient psychiatric research has become difficult due to
economic pressure. As for antidepressant drugs and vari-
ous types of psychotherapy, psychodynamic psychother-
apy is unlikely to be a universal therapy for depression
and progress depends on identifying its most appropriate
ecological niche [66].
This study is the first to address the issue of the eco-
nomic evaluation of inpatient psychotherapy. Psycho-
therapy is costly in time and money; thus evidence of
the cost-effectiveness and cost-utility of a short adjunct-
ive psychotherapy as an alternative treatment to longer
hospitalization or outpatient aftercare would be an
important healthcare finding.
The project has a direct impact on the functioning
of the inpatient clinical unit. The implementation of a
manualized practice (for psychotherapy and psychiatric
treatment-as-usual) will help to improve the organization
of the inpatient care and to better structure the clin-
icians’ training.
Strengths and limitations
This research has notable strength in its randomized
controlled design. It compares the intervention to the
state-of-the-art inpatient treatment of depression [10].
Treatments are manualized and adherence to the psy-
chotherapy is monitored. Most important potential con-
founders predicting depression outcome are assessed.
Despite these strengths, this research has some import-
ant limitations. It doesn’t compare the intervention to
another active treatment. The intervention is added to
the treatment-as-usual. One might argue that patient in
the intervention arm will get more therapeutic attention.
However, from a quantitative point of view, 12 hours of
therapy over 4 weeks of hospitalisation doesn’t add
much of therapeutic attention. Furthermore, we believe
it would be unethical to compare psychotherapy and
clinical management to medication and clinical manage-
ment. First, medication and clinical management is
probably the most used treatment for inpatients with
major depressive episode. Second, evidence suggest
that a combined treatment is recommended for severe
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Most patients will benefit of ongoing pharmacological
and/or psychotherapeutic treatment in both groups after
hospital discharged.
Future research
Within a total health care delivery system, it is important
to optimize the integration of inpatient and outpatient ser-
vices. The next step in this project will be to select
patients according to their response to the inpatient treat-
ment and control for the outpatient psychotherapeutic
after-care, as this has been neglected up till now [21].
From a research perspective, if some evidence that
IBPP is effective were to be found, it would then be inter-
esting to have a better understanding of the processes by
which IBPP achieves its results. The data gathered in this
trial will constitute a “gold mine” for process-outcome
studies in psychodynamic psychotherapy.
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